OBY_RevisedSupplement_Diabetes_Care_CleanR2.1.pdf (1.55 MB)

Personalized Postprandial Glucose Response–Targeting Diet Versus Mediterranean Diet for Glycemic Control in Prediabetes

Download (1.55 MB)
figure
posted on 23.07.2021, 16:38 by Orly Ben-Yacov, Anastasia Godneva, Michal Rein, Smadar Shilo, Dmitry Kolobkov, Netta Koren, Noa Cohen Dolev, Tamara Travinsky Shmul, Bat Chen Wolf, Noa Kosower, Keren Sagiv, Maya Lotan-Pompan, Niv Zmora, Adina Weinberger, Eran Elinav, Eran Segal
OBJECTIVE To compare the clinical effects of a Personalized Postprandial-Targeting (PPT) diet vs a Mediterranean (MED) diet, on glycemic control and metabolic health in prediabetes.

RESEARCH DESIGN AND METHODS We randomly assigned adults with prediabetes (n=225) to follow a MED diet or a PPT diet for a 6-month dietary intervention and additional 6-month follow-up. The PPT diet relies on a machine-learning algorithm that integrates clinical and microbiome features to predict personal postprandial-glucose-responses (PPGR). During the intervention, all participants were connected to continuous glucose monitoring (CGM) and self-reported dietary intake using a smartphone application.

RESULTS Among 225 participants randomized (58.7% women; mean±SD age, 50±7 years; BMI, 31.3±5.8 kg/m2; HbA1c, 5.9±0.2% (41±2.4 mmol/mol); fasting plasma glucose 114±12mg/dl [6.33±0.67 mmol/L]), 200 (89%) completed the 6-month intervention. A total of 177 participants additionally contributed 12-month follow-up data. Both interventions reduced the daily time with glucose levels above 140 mg/dl (7.8 mmol/L) and HbA1c levels, but reductions were significantly greater in PPT compared to MED. The mean 6-month change in ‘time above 140 mg/dl (7.8 mmol/L)’ was -0.3±0.8 hour/day and -1.3±1.5 hour/day for MED and PPT, respectively (95% CI between-group difference, -1.29 to -0.66; p<0.001). The mean 6-month change in HbA1c was -0.08±0.19% (-0.9±2.1 mmol/mol) and -0.16±0.24% (-1.7±2.6 mmol/mol) for MED and PPT, respectively (95% CI between-group difference, -0.14 to -0.02; p=0.007). The significant between-group differences maintained at 12-month follow-up. No significant differences were noted between the groups in an oral glucose tolerance test (OGTT, CGM-measured).

CONCLUSIONS In this clinical trial in prediabetes, a PPT diet improved glycemic control significantly more than a MED diet as measured by daily time of glucose levels above 140 mg/dl (7.8 mmol/L) and HbA1c. These findings may have implications to dietary advice in clinical practice.

Funding

The funding for the study was provided jointly by the companies Janssen Pharmaceuticals, Inc. and DayTwo.

History